We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Natural Substance May Treat Prostate Cancer

By HospiMedica staff writers
Posted on 04 May 2001
A laboratory study has found that a natural substance called quercetin--found in onions, apples, red wine, and tea—may represent a new approach for preventing and treating prostate cancer. More...
Results of the study, conducted by researchers at Mayo Clinic (Rochester, MN, USA), were published in the March issue of Carcinogenesis.

In the study, quercetin demonstrated significant activity against the androgen receptor in human prostate cancer cells. Androgens in the prostate gland are mediated by this receptor. Current treatment for advanced prostate cancer includes suppressing androgen by medication or surgery. However, the cancer recurs in one or two years in about 80% of patients after having the therapy, which may be due to mutations in the androgen receptor. According to Dr. Nianzeng Xing, Ph.D., a Mayo Clinic researcher involved in the study, it appears that the cancer learns to grow in the prostate with less hormone or even without the need of hormones.

"In view of that fact,” said Dr. Xing, "a more effective strategy in the fight against prostate cancer may to minmize or eliminate the amount of the androgen receptor.”
Quercetin may make this possible. The next research step will be to study quercetin's effects in a mouse model with prostate cancer.




Related Links:
Mayo Clinic

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Mobile X-Ray System
K4W
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.